Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in gilbert's syndrome

Clinical Science

Volumn 125, Issue 5, 2013, Pages 257-264

  Wallner, Marlies ^a   Marculescu, Rodrig ^b   Doberer, Daniel ^b   Wolzt, Michael ^b   Wagner, Oswald ^b   Vitek, Libor ^c   Bulmer, Andrew C ^d   Wagner, Karl Heinz ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CHARLES UNIVERSITY   (Czech Republic)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Apolipoprotein; Cardiovascular disease (CVD); Gilbert's syndrome; Lipid metabolism; Low density lipoprotein (LDL) subfractions; Unconjugated bilirubin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILIRUBIN; BIOLOGICAL MARKER; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GILBERT DISEASE; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPOCHOLESTEROLEMIA; INFLAMMATION; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ADIPOSITY; ADULT; AGING; ANIMALS; BILIRUBIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FEMALE; GILBERT DISEASE; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; RATS; RATS, GUNN; YOUNG ADULT;

EID: 84878535419     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120661     Document Type: Article

References (42)

1. Novotny, L. and Vitek, L. (2003) Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. 228, 568-571
2. Temme, E. H., Zhang, J., Schouten, E. G. and Kesteloot, H. (2001) Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12, 887-894
3. Zucker, S. D., Horn, P. S. and Sherman, K. E. (2004) Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 40, 827-835
4. Horsfall, L. J., Rait, G., Walters, K., Swallow, D. M., Pereira, S. P., Nazareth, I. and Petersen, I. (2011) Serum bilirubin and risk of respiratory disease and death. JAMA, J. Am. Med. Assoc. 305, 691-697
5. *28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 567-574
6. Bosma,P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N., Jansen, P. L., Oude Elferink, R. P. et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175
7. Fertrin, K. Y., Goncalves, M. S., Saad, S. T. and Costa, F. F. (2002) Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am. J. Med. Genet. 108, 117-119
8. Stocker, R. (2004) Antioxidant activities of bile pigments. Antioxid. Redox Signaling 6, 841-849
9. Bulmer, A. C., Blanchfield, J. T., Toth, I., Fassett, R. G. and Coombes, J. S. (2008) Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199, 390-396
10. Muchova, L., Vanova, K., Zelenka, J., Lenicek, M., Petr, T., Vejrazka, M., Sticova, E., Vreman, H. J., Wong, R. J. and Vitek, L. (2011) Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress. J. Cell. Mol. Med. 15, 1156-1165
11. Dennery, P. A., McDonagh, A. F., Spitz, D. R., Rodgers, P. A. and Stevenson, D. K. (1995) Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radical Biol. Med. 19, 395-404
12. Schwertner, H. A., Jackson, W. G. and Tolan, G. (1994) Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18-23
13. Boon, A. C., Hawkins, C. L., Bisht, K., Coombes, J. S., Bakrania, B., Wagner, K. H. and Bulmer, A. C. (2012) Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radical Biol. Med. 52, 2120-2127
14. Yoshino, S., Hamasaki, S., Ishida, S., Kataoka, T., Yoshikawa, A., Oketani, N., Saihara, K., Okui, H., Shinsato, T., Ichiki, H. et al. (2011) Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J. Atheroscler. Thromb. 18, 403-412
15. Ollinger, R., Bilban, M., Erat, A., Froio, A., McDaid, J., Tyagi, S., Csizmadia, E., Graça-Souza, A. V., Liloia, A., Soares, M. P. et al. (2005) Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112, 1030-1039
16. Ryter, S. W. and Choi, A. M. (2009) Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am. J. Respir. Cell Mol. Biol. 41, 251-260
17. Tapan, S., Karadurmus, N., Dogru, T., Ercin, C. N., Tasci, I., Bilgi, C., Kurt, I. and Erbil, M. K. (2011) Decreased small dense LDL levels in Gilbert's syndrome. Clin. Biochem. 44, 300-303
18. Ocadlik, I., Hlinstakova, S. and Oravec, S. (2011) Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum. Neuro. Endocrinol. Lett. 32, 360-364
19. Otvos, J. D., Mora, S., Shalaurova, I., Greenland, P., Mackey, Jr, R. H. and Goff, D. C. (2011) Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 5, 105-113
20. Chowdhury, J. R., Kondapalli, R. and Chowdhury, N. R. (1993) Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. Adv. Vet. Sci. Comp. Med. 37, 149-173
21. Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K. K., Thompson, A., Wood, A. M., Lewington, S., Sattar, N., Packard, C. J. et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA, J. Am. Med. Assoc. 302, 1993-2000
22. Van Gaal, L. F., Mertens, I. L. and De Block, C. E. (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880
23. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. and Ridker, P. M. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, J. Am. Med. Assoc. 286, 327-334
24. Yang, R. Z., Lee, M. J., Hu, H., Pollin, T. I., Ryan, A. S., Nicklas, B. J., Snitker, S., Horenstein, R. B., Hull, K., Goldberg, N. H. et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 3, e287
25. King, V. L., Thompson, J. and Tannock, L. R. (2011) Serum amyloid A in atherosclerosis. Curr. Opin. Lipidol. 22, 302-307
26. Hoefner, D. M., Hodel, S. D., O'Brien, J. F., Branum, E. L., Sun, D., Meissner, I. and McConnell, J. P. (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin. Chem. 47, 266-274
27. Elmadfa, I., Freisling, H., Nowak, V. and Hofsẗadter, D. (2009) Austrian Nutrition Report 2008, Federal Ministry of Health, Vienna
28. Choi, S. H., Yun, K. E. and Choi, H. J. (2013) Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr. Metab. Cardiovasc. Dis. 23, 31-37
29. Kwon, K. M., Kam, J. H., Kim, M. Y., Chung, C. H., Kim, J. K., Linton, J. A., Eom, A., Koh, S. B. and Kang, H. T. (2011) Inverse association between total bilirubin and metabolic syndrome in rural Korean women. J. Womens Health 20, 963-969
30. Bulmer, A. C., Verkade, H. J. and Wagner, K. H. (2012) Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog. Lipid Res. 52, 193-205
31. Andersson, C., Weeke, P., Fosbol, E. L., Brendorp, B., Kober, L., Coutinho, W., Sharma, A. M., Van Gaal, L., Finer, N., James, W. P., SCOUT Executive Steering Committee; SCOUT investigators, W. P. et al. (2009) Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metab., Clin. Exp. 58, 1109-1115
32. Leitzmann, M. F., Moore, S. C., Koster, A., Harris, T. B., Park, Y., Hollenbeck, A. and Schatzkin, A. (2011) Waist circumference as compared with body-mass index in predicting mortality from specific causes. PLoS ONE 6, e18582
33. Vitek, L., Kraslova, I., Muchova, L., Novotny, L. and Yamaguchi, T. (2007) Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J. Gastroenterol. Hepatol. 22, 841-845
34. Lippi, G., Targher, G., Montagnana, M., Salvagno, G. L. and Guidi, G. C. (2009) Bilirubin concentration and cardiovascular risk profile. Liver Int. 29, 315-316
35. Zhou, J., Tracy, T. S. and Remmel, R. P. (2011) Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab. Dispos. 39, 322-329
36. Berneis, K. K. and Krauss, R. M. (2002) Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res. 43, 1363-1379
37. Smith, Jr, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W. et al. (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation 58, 2432-2446
38. Holme, I., Aastveit, A. H., Hammar, N., Jungner, I. and Walldius, G. (2009) Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 265, 275-287
39. Walldius, G. and Jungner, I. (2006) The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J. Intern. Med. 259, 493-519
40. Walldius, G. and Jungner, I. (2007) Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A - new risk factors and targets for therapy. Nutr. Metab. Cardiovasc. Dis. 17, 565-571
41. Johnson, B. D., Kip, K. E., Marroquin, O. C., Ridker, P. M., Kelsey, S. F., Shaw, L. J., Pepine, C. J., Sharaf, B., Bairey Merz, C. N., Sopko, G. et al.; National Heart, Lung, and Blood Institute (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109, 726-732
42. Hwang, H. J., Lee, S. W. and Kim, S. H. (2011) Relationship between bilirubin and C-reactive protein. Clin. Chem. Lab. Med. 49, 1823-1828